PCGF2

Across TCGA pan-cancer cohorts, PCGF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCGF2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PCGF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PCGF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where PCGF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.711	0.970	<.001	47	view →
PDAC	OS	Tertile	All	0.374	0.834	<.001	35	view →
CCRCC	OS	Tertile	All	0.922	0.627	.001	26	view →
LSCC	OS	Median	All	0.830	0.949	.033	2	view →
LUAD	OS	Median	II,III,IV	0.999	0.863	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCGF2–HNSC (OS)

Open the HNSC breakdown →